Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review

April 2016 | Volume 15 | Issue 4 | Original Article | 414 | Copyright © April 2016


Lauren R. Seale BS,a Ariana N. Eglini BA,b and Amy J. McMichael MDc

aUniversity of Michigan Medical School, Ann Arbor, MI
bWake Forest University School of Medicine, Winston-Salem, NC
cDepartment of Dermatology, Wake Forest University School of Medicine, Winston Salem, NC

  1. Kossard, S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol. 1994;130(6):770-774.
  2. Dutasteride patient information. In: UpToDate, UpToDate, Waltham, MA. Accessed July 2015. http://www.uptodate.com/contents/dutasteride-patient-drug-information?source=search_result&search=dutasteride+patient+information&selectedTitle=1~29.
  3. Finasteride patient information. In: UpToDate, UpToDate, Waltham, MA. Accessed July 2015. http://www.uptodate.com/contents/finasteride-patient-drug-information?source=search_result&search=finasteride+drug+information&selectedTitle=2~49.
  4. Gubelin Harcha W, Barboza Martínez J, Tsai TF et al A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.
  5. Eun HC, Kwon OS, Yeon JH, et al Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double blind, placebo-controlled, phase III study. J Am Acad Dermatoly. 2010;63(2):252-258.
  6. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 pt 1):578-589.
  7. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.
  8. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91-95.
  9. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4(3):282-284.
  10. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 pt 1):768-776.
    11. .
  11. Olzewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4(5)637-640.
  12. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437-443.
  13. Belknap SM, Aslam I, Kiguradze T, et al. Adverse event reporting in clinical trials of finasteride for androgenetic alopecia: a meta analysis.JAMA Dermatol. 2015;151(6):600-606.
  14. Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47(5):733-739.
  15. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.
  16. Thai KE, Sinclair RD. Finasteride for female androgenetic alopecia. Br J Dermatol. 2002;147(4):812-813.
  17. Moreno-Ramírez D, Camacho Martínez F. Frontal fibrosing alopecia: a survey in 16 patients. J Eur Acad Dermatol. 2005;19(6):700-705.
  18. Hong JB, Chiu HC, Chan JY, Chen RJ, Lin SJ. A woman with iatrogenic alopecia responding to finasteride. Br J Dermatol. 2007;156(4):754-755.
  19. Katoulis A, Georgala, Bozi E, Papadavid E, Kalogeromitros D, Stavrianeas N. Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus. J Eur Acad Dermatol Venereol. 2009;23(5):580-582.
  20. Boychenko O, Bernstein RM, Schweiger ES. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis. 2012;90(2):73-76.
  21. Pérez-Rodríguez IM, García-Melendez ME, Eichelmann K, Vázquez-Martínez O, Ocampo-Candiani J. Hyperpigmentation following treatment of frontal fibrosing alopecia. Case Rep Dermatol. 2013;5(3):357-362.
  22. Trüeb RM; Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209(3):202-207.
  23. Tosti A, Piraccini BM, Iorrizo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005;52(1):55-60.
  24. Iorrizo M, Vincenzi C, Voudouris S, Piraccini, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142(3):298-302.
  25. Georgala S, Katoulis AC, Befon A, Danopoulou I, Georgala C. Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride. J Am Acad Dermatol. 2009;61(1):157-158.
  26. Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(2):211-214.
  27. Oliveira-Soares R, E Silva JM, Correia MP, André MC. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology. 2013;5(1):22-25.
  28. Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23(3):142-145.
  29. Ladizinski B, Bazakas A, Selim MA, Olsen EA. Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. J Am Acad Dermatol. 2013;68(5):749-755.
  30. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521-525.
  31. Vaño-Galván S, Molina-Ruiz AM, Serrano-Falcón C, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70(4):670-678.
  32. van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;4:CD010334.
  33. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;1:CD011066.
  34. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.
  35. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258.
  36. National Institutes of Health Genetic and Rare Diseases Information Center. Adverse events of 5-alpha-reductase inhibitors. Available at: http:// www.rarediseases.info.nih.gov/gard/12407/post-finasteride-syndrome/resources/1 . Accessed March 2016.
  37. Post-Finasteride Syndrome Foundation. Post-Finasteride Syndrome: Overview. Available at: http://www.pfsfoundation.org/post-finasteride-syndrome-overview/. Accessed March 2016.
  38. Bitzer J, Giraldi A, Pfaus J. Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1). J Sex Med. 2013;10(1):36-49.
  39. Gellad WF, Flynn KE, Alexander GC. Evalulation of flibanserin: science and advocacy at the FDA.JAMA. 2015;314(9):869-870.

AUTHOR CORRESPONDENCE

Lauren R. Seale BS…….............. lseale@med.umich.edu
Close Menu